Epygenix Therapeutics is a clinical stage precision medicine-based biopharmaceutical company developing drugs for rare and intractable forms of genetic epilepsy, such as Dravet syndrome and Lennox-Gastaut syndrome.

The ARGUS (EPX-100; Clemizole HCI) trial is currently recruiting. More information on this multi-national, multi-center trial may be found on clinicaltrials.gov.

If you have further questions, please contact at [email protected] or Da[email protected]